Awardee OrganizationUT SOUTHWESTERN MEDICAL CENTER
Description
Abstract Text
The interdisciplinary Chemistry and Cancer (CC) Program is uniquely situated in Simmons Comprehensive
Cancer Center (SCCC) to bridge fundamental biology research with the discovery of novel therapies for the
treatment of cancer. CC has facilitated numerous intraprogrammatic and interprogrammatic collaborations,
which have resulted in new insights into cancer biology and drug discovery of high clinical applicability. CC
combines the expertise of synthetic and medicinal chemists, molecular and structural biologists, biochemists,
chemical biologists, pharmacologists, and clinician scientists to discover, design, and optimize drug-like small
molecules that regulate biological pathways deregulated in cancer. CC’s discovery platform is guided by the
hypothesis that an interdisciplinary and chemically focused approach to cancer biology will provide new avenues
for discovery in cancer prevention and treatment. The CC Program is co-led by Jef De Brabander, PhD, and
Uttam Tambar, PhD, and is composed of 22 members who are drawn from seven departments on campus. The
CC Scientific Program is defined by three specific aims: (1) Identification of Molecular Targets of Novel Anti-
Cancer Agents, (2) Biochemical Dissection of Regulatory Pathways Relevant to Human Cancer, and (3)
Structure-Based Design of Chemicals that Perturb Cancer-Relevant Signaling Pathways.
The CC Program focuses on acceleration of the continued translation of chemical discoveries made at the UT
Southwestern Medical Center (UTSW) and SCCC to the clinic, the initiation of early-stage translational studies,
and the licensing of mid- to late-stage preclinical studies. The CC Program will continue to prioritize research
programs that impact cancers that are prevalent in the SCCC catchment area, such as colorectal, lung, kidney,
and liver cancers. In addition, the CC Program will promote interprogrammatic and intraprogrammatic
collaborations and explore new projects in the three specific aims.
Total direct peer-reviewed funding to the CC Program is $5.2M, with $2.6M (51%) from the NCI. CC Program
members have authored 253 peer-reviewed publications since 2014, of which 17% were intraprogrammatic,
40% interprogrammatic, and 36% were in journals with impact factors ≥ 10.
No Sub Projects information available for 5P30CA142543-13 7272
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P30CA142543-13 7272
Patents
No Patents information available for 5P30CA142543-13 7272
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P30CA142543-13 7272
Clinical Studies
No Clinical Studies information available for 5P30CA142543-13 7272
News and More
Related News Releases
No news release information available for 5P30CA142543-13 7272
History
No Historical information available for 5P30CA142543-13 7272
Similar Projects
No Similar Projects information available for 5P30CA142543-13 7272